What Synvisc-One Treats: Main Uses and Benefits

Synvisc-One (hylan G-F 20) is a specific type of injection applied in addressing symptoms related to physical discomfort associated with osteoarthritis (OA) of the knee. This approach is often used during phases when symptoms become more noticeable. Its application is relevant in contexts marked by increased discomfort or tension, which may assist with managing symptoms related to physical discomfort.

It is commonly used across conditions presenting with acute episodes and is relevant when supportive symptom management is appropriate.

The areas of use focus on managing symptom clusters that may become intense or disruptive, including symptoms related to physical discomfort and symptoms that interfere with daily functioning. Synvisc-One is relevant in conditions characterized by periods of heightened symptoms. It supports general well-being during symptomatic phases, contributing to improved comfort during periods of heightened symptoms. By easing the overall symptom burden, it assists with maintaining functional stability.

Quick Fact: Supports general well-being during symptomatic phases.

Who Can and Cannot Use Synvisc-One?

Eligibility for Synvisc-One (hylan G-F 20) is strictly defined by regulatory documents, focusing primarily on patient history, age, and the condition of the knee joint. The product is indicated for adults with symptomatic osteoarthritis of the knee who have not responded adequately to conservative nonpharmacologic therapy and simple analgesics.

Official Contraindications

Use is contraindicated (absolutely prohibited) in specific patient populations:

• Patients with known hypersensitivity or allergy to hyaluronan or sodium hyaluronate preparations.
• Patients who have knee joint infections or skin diseases/infections in the area of the injection site.
• Patients with venous or lymphatic stasis in the limb to be treated.

Populations with Use Not Established

Safety and effectiveness have not been established in the following groups, and use is generally not recommended:

• Pediatric patients (those le 21 years of age).
• Pregnant women.
• Lactating (nursing) women.

Caution is advised for patients with known allergies to avian proteins (e.g., poultry, feathers, eggs), given the biologic origin of hylan G-F 20.

Official Interaction Profile

The interaction profile for Synvisc-One (Hylan G-F 20) is highly restricted by its non-systemic delivery via intra-articular injection. The officially documented interactions primarily concern physical and chemical incompatibility during the administration procedure, rather than systemic drug–drug interactions.

Regulatory Summary

The regulatory structure defining the Synvisc-One interaction profile is limited to procedural and physical constraints. The key constraint is the mandatory non-concomitant use of quaternary ammonium salts due to the risk of chemical precipitation of the Hylan G-F 20. This narrow scope reflects the product's function as a localized viscosupplement, which is not subjected to traditional pharmacokinetic or pharmacodynamic systemic drug interaction analysis.

The mechanism of action involves the intra-articular administration of hylan G-F 20, a crosslinked derivative of hyaluronan (HA). This polymer possesses substantially higher molecular weight and viscoelastic properties compared to the endogenous HA found in the synovial fluid. This differential allows the hylan G-F 20 to restore the viscoelasticity of the synovial fluid within the joint space. The substance then provides mechanical support by altering the local load distribution and dampening the magnitude of compressive and shear forces applied to the articular cartilage. Concurrently, hylan G-F 20 engages in direct receptor interaction with CD44 on the surface of synoviocytes and chondrocytes. This molecular binding facilitates the modulation of local cell signaling pathways within the joint environment. The resulting mechanistic cascade involves the regulation of the intra-articular biochemical environment, which consists of cytokines and matrix metalloproteinases.

How to Use Synvisc-One

Synvisc-One is administered based on a specialized, non-series usage regimen defined strictly by regulatory guidelines. The only approved route of administration is a single intra-articular injection placed directly into the synovial space of the knee joint. This targeted route is fundamental to its function as a viscosupplementation agent.

The standard adult dosing requires the injection of the full contents of the syringe, which is 6 mL of the viscoelastic solution containing 48 mg of Hylan G-F 20. This single injection constitutes the entire treatment course. The therapy is intermittent, meaning it is not a continuous therapy; however, regulatory documents note that the treatment may be repeated if the patient's symptoms return over time, typically after an interval of approximately six months.

The administration is subject to several official procedural conditions. The injection must be performed by a qualified healthcare professional under strict aseptic technique. A critical requirement is the mandatory removal of any existing joint effusion (excess fluid) from the knee prior to the injection, and the label specifies that a separate syringe must be used for this step. Furthermore, official documentation notes that the safety and effectiveness have not been established in pediatric patients (those ≤ 21 years) or in pregnant and lactating women.

Research evidence / Overview of studies for Synvisc-One

Evidence for Use in Osteoarthritis of the Knee

Research exploring Synvisc-One has been studied for conditions characterized by functional limitations in adults diagnosed with osteoarthritis (OA) of the knee, particularly those whose symptoms were persistent following conservative non-pharmacologic therapies. The primary body of evidence comes from Randomized Controlled Trials (RCTs). These studies were designed to compare the injection against an inactive placebo injection to assess outcomes related to physical discomfort. Studies monitored patient-reported outcomes describing perceived discomfort, focusing mainly on scores for knee pain during movement and measures of physical functioning in daily life.

Studies report how symptoms evolved in the observed populations over defined time intervals. Findings were mixed when comparing the results across different meta-analyses, and some evidence contributes to understanding symptom patterns rather than providing a consistent outcome across all trials.

Research Examining Different Comparator Treatments

Studies have explored the use of Synvisc-One in trials where it was compared not only against an inactive placebo but also against other active comparator treatments, such as other viscosupplementation products. Research examined how these different comparator treatments were evaluated alongside outcomes related to physical discomfort over the defined study period.

Findings indicate patterns related to the different treatments monitored. Studies monitored findings related to the outcomes of the comparator injections, but evidence quality varies across studies when considering the full scope of different products and comparison research designs. Research highlights changes measured during the study period, but findings were mixed regarding broad comparative outcomes.

Evidence in Specific Patient Groups and Limitations

Research involving Synvisc-One focused on the populations studied: adults diagnosed with symptomatic knee osteoarthritis. However, data for certain groups remain insufficient, and the results apply only to the populations studied. Data establishing the safety and effectiveness of the injection are unavailable for pediatric patients (age 21 or younger), pregnant women, or nursing mothers.

Furthermore, research has noted a noticeable intra-articular placebo response in some trials, which contributed to the difficulty in assessing treatment outcomes. Evidence remains limited for long-term outcomes, as most primary follow-up durations were limited to 26 weeks (six months), meaning the need for continued research in this area is recognized.

Key Studies & References SYNVISC ONE® HYLAN G-F 20 Prescribing Information - Sanofi U.S.

Common questions about Synvisc-One (FAQ)

Q: How is Synvisc-One different from the Synvisc 3-shot treatment?

According to official product information, Synvisc-One and Synvisc contain the same active ingredient, hylan G-F 20. The primary difference is in the dosing regimen: Synvisc-One is provided as a single injection, whereas Synvisc is administered as a course of three separate injections.

Q: Can Synvisc-One cause an allergic reaction, and what are the signs?

Regulatory documents list signs associated with allergic reactions. Less severe signs may include a rash, hives, or itching. It is noted that serious allergic reactions, such as anaphylaxis (which involves throat swelling or difficulty breathing), have been reported.

Q: Why do some doctors recommend Synvisc-One over a standard cortisone shot?

Regulatory-referenced research has formally studied Synvisc-One against intra-articular corticosteroid (cortisone) injections given into the joint. This research involves examining outcomes related to pain relief and physical function for both treatments over defined periods of time.

Q: Is Synvisc-One used for conditions other than knee osteoarthritis?

Official product information states that the safety and effectiveness of Synvisc-One have not been established for treating conditions other than symptomatic osteoarthritis of the knee. This means the product is only officially indicated for use in the knee joint for this specific condition.

Q: What are the typical timeframes for feeling relief after the injection?

Studies supporting the use of the product have examined the timeframes for patients to report relief. Evidence indicates that patients may start to notice pain relief around four weeks after the injection, and the overall pattern of symptom change may become more noticeable after approximately 12 weeks.

Q: What precautions or limitations are advised for activities following the injection?

Official patient safety information describes the limitation of strenuous or prolonged weight-bearing activities, such as jogging or heavy lifting, for approximately 48 hours following the injection.

Q: Do insurance plans typically cover the cost of Synvisc-One?

Official sources related to reimbursement note that coverage for Synvisc-One varies significantly by insurer. Whether the cost is covered depends on the patient's specific insurance plan, state of residence, and individual eligibility status.

Q: Are there specific research studies about using Synvisc-One in active patients?

Records from official clinical trial registries show that research has been formally conducted to study the use of Synvisc-One in patient populations described as younger and active patients who have knee osteoarthritis.

Q: Can Synvisc-One be used in other joints besides the knee?

Regulatory documents specify that the product is only indicated for injection into the knee. The safety and effectiveness of using Synvisc-One in any joints other than the knee have not been established in official product information.

Storage and Disposal of Synvisc-One: Regulatory Requirements

Official regulatory documents define the required handling and storage conditions for Synvisc-One (hylan G-F 20) to maintain product stability and integrity.

The established storage conditions prohibit freezing and require light protection to preserve the viscoelastic fluid. The disposal requirement is mandatory due to the syringe's single-use, sterile contents, ensuring that any unused product is discarded according to medical facility waste procedures and the product is not re-sterilized.